Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZ358 in Congenital Hyperinsulinism
NCT04538989Phase 2Completed
- Sponsor
- Rezolute, Inc.
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of ersodetug in congenital hyperinsulinism (HI), sponsored by Rezolute, Inc.. Started Feb 2020; status: completed.
02
Drugs
ersodetug
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT04538989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538989.